Patient out-of-pocket costs for antihypertensive single pill combination products with cost caps.

Authors

Catherine G Derington, Kyle Tong, Joshua A Jacobs, Brent M Egan, Jordan B King, Adam P Bress, Anthony Rodgers, Jaejin An, Kelsey B Bryant, Jordana B Cohen, Brandon K Bellows

Published in

Journal of human hypertension. Jul 04, 2026. Epub Jul 04, 2026.

Abstract

In this cross-sectional study of 5.8 million US adults with hypertension taking antihypertensive single-pill combination (SPC) products in the Medical Expenditure Panel Survey (2016-2022), the median out-of-pocket cost was $5.53 per SPC fill (interquartile range [IQR] $0.00-$12.70). A hypothetical small (e.g., $4/30 days) cost cap could reduce annual out-of-pocket spending by $152.9 million overall (median savings $5.35 (IQR $1.06-$12.81) per fill). A hypothetical large cost cap (e.g., $11/30 days) could reduce annual out-of-pocket spending by $61.2 million overall (median savings $2.27 (IQR $0.00-$11.28) per fill). Despite relatively low out-of-pocket costs, these spending reductions may lower patient financial burdens associated with antihypertensive SPC therapy.

PMID:
42401752
Bibliographic data and abstract were imported from PubMed on 05 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.